Fredag 1 November | 01:31:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-18 08:00 Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 - Årsstämma
2024-04-24 - Extra Bolagsstämma 2024
2024-02-23 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-04 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2023-01-12 - Extra Bolagsstämma 2022
2022-11-04 - Kvartalsrapport 2022-Q3
2022-08-05 - Kvartalsrapport 2022-Q2
2022-05-30 - Kvartalsrapport 2022-Q1
2022-05-23 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-11-08 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-13 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 - Årsstämma
2019-04-24 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-16 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-13 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 - Kvartalsrapport 2017-Q1
2017-05-11 - Årsstämma
2017-02-09 - Bokslutskommuniké 2016
2016-11-04 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga patienttillstånd inom kroniska inflammatoriska sjukdomar, samt diverse ledskador. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2023-11-22 15:00:00

SynAct Pharma AB (publ) (“SynAct”) today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) 2024 on May 23, 2024, has been appointed.

Pursuant to the instruction and charter for the Nomination Committee adopted at the AGM held on May 21, 2021, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors.

Based on the above, the Nomination Committee for the AGM 2024 has been established to consist of the following persons:

  • Niels Ankerstjerne Sloth, appointed by Bioinvest ApS
  • Per Colleen, appointed by TomEnterprise Public Capital AB
  • Anders Kronborg, appointed by Goodwind Holding GmbH
  • Uli Hacksell, Chairman of the Board of Directors

In total, the Nomination Committee represents approximately 18% of the total number of shares and votes in the company as of September 30, 2023.

The task of the Nomination Committee is to prepare and present proposals to the AGM regarding the Chairman of the AGM, the election of the Chairman and other members of the Board of Directors, the remuneration of the Board of Directors divided between the Chairman and the other members, any remuneration for Committee work and the election and remuneration of the auditor. Finally, the Nomination Committee will propose principles for the appointment of the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, c/o SynAct Pharma, Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to valberedning@synactpharma.com.

To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2024.

The Nomination Committee's proposals will be announced in the notice for the AGM 2024 and on SynAct’s web site.

The information was submitted, through the agency of the contact person below, for publication at 3.00 pm (CEST) on November 22, 2023.